CTOs on the Move

MEDZONE

www.medzone.ca

 
MEDZONE Inc. is a Montreal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medzone.ca
  • 9330 Boul Gouin E
    Montreal, QC CAN H1E 1C9
  • Phone: 514.648.3746

Executives

Name Title Contact Details

Similar Companies

Child Health Corporation Of America

Child Health Corporation of America (CHCA) is a legacy business alliance of children's hospitals. CHCA children's hospitals represented more than 20,000 physicians, 100,000 employees, $14 billion in revenue and $1.8 billion in overall medical, surgical and pharmaceutical products. CHCA's former Owner Hospitals are North America's leading children's hospitals and are widely known for their excellence in caring for America's children. In 2011, CHCA, the National Association of Children's Hospitals and Related Institutions (NACHRI) and its public policy affiliate National Association of Children's Hospitals (N.A.C.H.) merged to pool our strengths and talents, creating a new organization, the Children’s Hospital Association. We share members, a common board of trustees and new President and CEO Mark Wietecha. As one Association, we will continue to be champions for children’s health.  

Fitness Enterprises d/b/a First In Fitness

Fitness Enterprises d/b/a First In Fitness is a Barre, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Sports Medicine Institute

American Sports Medicine Institute is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ITC Nexus Dx

ITC is a wholly-owned subsidiary of Thoratec and develops, manufactures and markets medical devices used in three distinct segments of the medical field.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.